Announced details
Treatment of amyotrophic lateral sclerosis (ALS), and evaluation of biomarkers and clinical outcomes
Achieved the target enrollment of 200 patients
SEANOBI-ALS: enrollment completed for 200 patients (target); COMBAT-ALS: enrollment completed for 234 patients
The NIH provides funding, and the trial is supported by a grant from NINDS.
The NIH and its research institute, NINDS. Location, representative, capital, and year established: not disclosed.
NCT 06743776 (clinical trial registration number); expiration date: not disclosed
La Jolla, California, U.S. (the Company's headquarters)
$22 million (approximately ¥3.5 billion) grant
No impact on results for the fiscal year ending December 2026
The company does not address Offering price.
U.S. National Institutes of Health (NIH), NINDS, and References 1–3
| Item | Details |
|---|---|
| Names of Products / Services Covered | MN-166 (ibudilast), SEANOBI-ALS (Expand Access Protocol clinical trial) |
| Counterparty | U.S. National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) |
| Counterparty overview | The NIH and its research institute, NINDS. Location, representative, capital, and year established: not disclosed. |
| Relationship with the Company | The NIH provides funding, and the trial is supported by a grant from NINDS. |
| Contract Value | $22 million (approximately ¥3.5 billion) grant |
| Applicable area | Treatment of amyotrophic lateral sclerosis (ALS), and evaluation of biomarkers and clinical outcomes |
| Registration number and expiry date | NCT 06743776 (clinical trial registration number); expiration date: not disclosed |
| Location | La Jolla, California, U.S. (the Company's headquarters) |
| Quantitative Effects | Achieved the target enrollment of 200 patients |
| Usage history | SEANOBI-ALS: enrollment completed for 200 patients (target); COMBAT-ALS: enrollment completed for 234 patients |
| Impact on Business Performance | No impact on results for the fiscal year ending December 2026 |
| Source | U.S. National Institutes of Health (NIH), NINDS, and References 1–3 |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The NIH-funded SEANOBI-ALS study is intended to collect important ALS biomarker and clinical outcome data and provide access to MN-166 treatment for patients who are unable to participate in other clinical trials.